Table 2 Correlation between RI-LR and clinicopathological features, n (%).
Characteristics | Low-risk group (N = 17) | High-risk group (N = 26) | P |
|---|---|---|---|
Age, years, (\(\stackrel{-}{x}\)±s) | 60.53 ± 13.87 | 65.88 ± 11.27 | 0.194 |
Tumor grade | 0.055 | ||
I–II | 25 (96.2) | 12 (70.6) | |
III | 1 (3.8) | 5 (29.4) | |
Ki-67 expression | 0.369 | ||
< 15% | 16 (61.5) | 7 (41.2) | |
15–30% | 7 (26.9) | 8 (47.1) | |
> 30% | 3 (11.5) | 2 (11.8) | |
Tumour T stage | 0.650 | ||
T1 | 12 (46.2) | 7 (41.2) | |
T2 | 13 (50.0) | 10 (58.8) | |
T3 | 1 (3.8) | 0 (0.0) | |
Tumour N stage, n (%) | < 0.001 | ||
N0 | 21 (80.8) | 2 (11.8) | |
N1 | 3 (11.5) | 9 (52.9) | |
N2 | 2 (7.7) | 4 (23.5) | |
N3 | 0 (0.0) | 2 (11.8) | |
LVI | 0.356 | ||
Absent/focal | 20 (76.9) | 10 (58.8) | |
Prominent | 6 (23.1) | 7 (41.2) | |
ER/PR status | 0.828 | ||
Positive | 26 (100.0) | 16 (94.1) | |
Negative | 0 (0.0) | 1 (5.9) | |
HER2 status | 0.643 | ||
Positive | 23 (88.5) | 15 (88.2) | |
Negative | 3 (11.5) | 2 (11.8) | |
